COMMUNIQUÉS West-GlobeNewswire

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
21/05/2026
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]
ODDIFACT Receives European Commission Orphan Drug Designation for Infliximab in Kawasaki Disease
21/05/2026
European designation follows U.S. FDA Orphan Drug Designation previously granted for the same indication Landmark KIDCARE trial demonstrated superiority of infliximab over standard retreatment in resistant Kawasaki [...]
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
21/05/2026
Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS ® (zongertinib tablets) as an initial treatment option in HER2 ( ERBB2 )-mutant [...]
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
21/05/2026
Data to be presented across two posters at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Combined results evaluating AKY-2519 across several B7-H3 expressing tumor types, including metastatic [...]
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
21/05/2026
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunological disorders, [...]
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
21/05/2026
- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 - - Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher treatment [...]
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
21/05/2026
Preliminary mPFS of 15.2 months; mDOR not reached Robust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastases ORR 60% in patients with a broad spectrum of EGFR-NCMs, including PACC Dose [...]
HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 when Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccRCC) at the Upcoming 2026 ASCO Annual Meeting
21/05/2026
Data from Phase 1b dose escalation and expansion trial (n=69) shows a favorable safety profile, with manageable adverse events consistent with the known profiles of the respective drugs. Encouraging preliminary signals [...]
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
21/05/2026
Updated Phase 2 CRDF-004 data to be presented during ASCO 2026 rapid oral session on June 2, 2026; investor webcast scheduled for June 3, 2026 at 8:30 am ET to review the data SAN DIEGO, Calif., May 21, 2026 (GLOBE [...]
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development
21/05/2026
IRVINE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to fully [...]
Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at the 2026 ASCO Meeting
21/05/2026
Data for patients treated at or below recommended Phase 2 dose (RP2D) showed 84.6% disease control rate (33/39), including 3 partial responses (2 confirmed, 1 pending confirmation) RGT-61159 was well-tolerated at RP2Ds [...]
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
21/05/2026
Cash Runway Extended to Finance the Parkinson’s Program; Debt Paydown Improves Shareholder Equity Position Jupiter, FL, May 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the " [...]
Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference
21/05/2026
Daix (France), New York City (New York, Etats-Unis), le 21 mai 2026 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une [...]
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
21/05/2026
Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. ( [...]
ODDIFACT obtient la désignation médicament orphelin de la Commission Européenne pour l’infliximab dans la maladie de Kawasaki
21/05/2026
La désignation de la Commission Européenne fait suite à la désignation médicament orphelin de la FDA américaine, précédemment accordée pour la même indication L’essai clinique KIDCARE a démontré la supériorité de l’ [...]
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
21/05/2026
In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse events Activity of the combined regimen across all dose [...]
Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical Oncology Annual Meeting 2026
21/05/2026
Phase 1 Data Shows a 43% Overall Response Rate at the Recommended Phase 2 Dose and Durable Responses Exceeding One Year and Ongoing, with a Favorable Safety Profile Anti-Tumor Activity Seen Across ACC Subtypes and [...]
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
21/05/2026
Daix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies [...]
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
21/05/2026
ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multiple CR-001 clinical [...]

Pages